ProQR Therapeutics N.V.: ProQR Announces Year End 2024 Operating and Financial Results
Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...
Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively ...
ProQR Announces Year End 2024 Operating and Financial Results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for ...
PharmaTimes2d
Minoryx doses first patient with leriglitazone in Rett syndrome study
Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of ...
American Association of Individual Investors4d
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. Stock?
Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
Man quits job to run length of UK for charity
A delivery driver has quit his job to run the length of the UK in a month for a cause close to his heart. Jack Ward, 24, from ...
Johns Hopkins Medicine6d
Guillain-Barré Syndrome
What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...